Health Care [ 8/12 ] | Biotechnology [ 30/76 ]
NASDAQ | Common Stock
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States.
The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia.
It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform.
The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 26, 26 | -0.48 Increased by +42.86% | -0.38 Decreased by -24.90% |
| Nov 5, 25 | -0.41 Decreased by -10.81% | -0.39 Decreased by -5.59% |
| Aug 12, 25 | -0.38 Increased by +5.00% | -0.33 Decreased by -15.26% |
| May 14, 25 | -0.20 Increased by +47.37% | -0.36 Increased by +44.44% |
| Mar 24, 25 | -0.84 Decreased by -121.05% | -0.42 Decreased by -100.00% |
| Nov 12, 24 | -0.37 Increased by +7.50% | -0.40 Increased by +6.64% |
| Aug 13, 24 | -0.40 Decreased by -53.85% | -0.39 Decreased by -2.56% |
| May 13, 24 | -0.38 Increased by +28.30% | -0.42 Increased by +9.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by -100.00% | -66.16 M Increased by +40.57% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -54.89 M Decreased by -28.96% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -50.34 M Decreased by -14.90% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 15.00 M Increased by +N/A% | -26.14 M Increased by +31.31% | Decreased by -174.23% Decreased by N/A% |
| Dec 31, 24 | 952.25 K Decreased by -86.10% | -111.33 M Decreased by -202.22% | Decreased by -11.69 K% Decreased by -2.07 K% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -42.57 M Decreased by -10.14% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -43.82 M Decreased by -76.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -38.05 M Increased by +24.98% | Decreased by N/A% Decreased by N/A% |